[Development and estimation of nanosomal rifampicin].
A lab-scale method for preparation of rifampicin-loaded polybutylcyanoacrylate nanoparticles (nanosames) was developed. The biodistribution of the nanosome-entrapped rifampicin after its intravenous administration was studied on healthy mice. The nanoparticles provided significant liver and spleen accumulation of rifampicin. Modification of the nanoparticles surface with poloxamer 407 or poloxamine 908 led to optimization of the biodistribution: the concentrations of rifampicin in the lungs and plasma increased, whereas the liver accumulation decreased vs. the unmodified nanoparticles. The increased lung accumulation of rifampicin enhanced bacterial clearance in the lungs of the mice infected with M. tuberculosis. The results showed that the use of the nanoparticles for optimization of the drug biodistribution was effective for increasing the efficacy of antiinfective chemotherapy.
Oganesian
E A
EA
Bud'ko
A P
AP
Stukalov
Iu V
IuV
Liubimov
I I
II
Biketov
S F
SF
Sveshnikov
P G
PG
KheĭfetsL B
Gel'perina
S E
SE
D000818:Animals; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004195:Disease Models, Animal; D007275:Injections, Intravenous; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D049329:Nanostructures / Q000737:chemistry*; D036103:Nanotechnology / Q000379:methods*; D012293:Rifampin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014376:Tuberculosis / Q000188:drug therapy
D000904:Antibiotics, Antitubercular; D012293:Rifampin